β-Amyloid Peptide: the Cell Compartment Multi-faceted Interaction in Alzheimer's Disease

Pasquale Picone1, Domenico Nuzzo2, Daniela Giacomazza3

  • 1Istituto per la Ricerca e l'Innovazione Biomedica (CNR-IRIB), Consiglio Nazionale delle Ricerche, 90146, Palermo, Italy. pasquale.picone@cnr.it.

Neurotoxicity Research
|December 8, 2019
PubMed

Insights

Alzheimer's disease involves amyloid beta (Aβ) aggregates interacting with cellular components. This review examines how Aβ

Area of Science:

  • Neuroscience
  • Cell Biology
  • Biochemistry

Background:

  • Alzheimer's disease (AD) is the most common dementia, marked by cognitive decline.
  • Amyloid beta (Aβ) aggregates (oligomers to fibrils) are key pathological markers in AD.
  • The precise neurodegenerative mechanisms in AD remain incompletely understood.

Purpose of the Study:

  • To review the impact of Aβ peptide interactions with cellular compartments.
  • To explore how different Aβ aggregate forms and sizes influence cellular pathology.
  • To analyze Aβ's role in altering organelle structure and function, leading to neurodegeneration.

Main Methods:

  • Literature review focusing on Aβ interactions with cellular components.
  • Analysis of studies investigating Aβ effects on plasma membrane, mitochondria, lysosomes, nucleus, and endoplasmic reticulum.
  • Examination of evidence linking Aβ-induced organelle dysfunction to neurodegenerative pathways.

Main Results:

  • Aβ peptides interact with various cellular organelles, including the plasma membrane, mitochondria, and nucleus.
  • The polymorphic nature of Aβ aggregates influences their interaction and cellular targets.
  • Aβ binding alters organelle structure and function, contributing to cellular dysfunction.

Conclusions:

  • Aβ interactions with cellular compartments are central to Alzheimer's disease pathogenesis.
  • Organelle dysfunction induced by Aβ aggregates triggers cellular death pathways.
  • Understanding these interactions is crucial for developing targeted AD therapies.

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.5K
Amyloid Fibrils03:03

Amyloid Fibrils

6.2K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
715